octet (Sartorius AG)
Sartorius AG is a verified supplier 
Sartorius AG manufactures this product 
99
Structured Review
Sartorius AG
octet
Octet, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 8612 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/article/Octet/custom%40octet%4042479900
Average 99 stars, based on 8612 article reviews
Octet, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 8612 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/article/Octet/custom%40octet%4042479900
Average 99 stars, based on 8612 article reviews
octet - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
Concentration Assay:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Binding Assay:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Ubiquitin Proteomics:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Analysis:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Labeling:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Cell Culture:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Construct:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Western Blot:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Enzyme-linked Immunosorbent Assay:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Sequencing:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Transfection:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Negative Control:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Centrifugation:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Control:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Recombinant:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Microscopy:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Incubation:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Comparison:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Virus:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using Transduction:Article Title: Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8 + T-cell activation. Article Snippet: , pB2M-IL2v, pB3-wtIL2, and pB3-IL2v. All constructs were validated by Sanger sequencing (HZYKANG Biotech, Hangzhou, China). HEK 293T cells were transfected AR TIC LE IN PR ES S ARTICLE IN PRESS using |